Effects of Detergents on the West Nile Virus Protease Activity

Overview

Journal Bioorg Med Chem

Specialties Biochemistry
Chemistry

Date 2009 Apr 17

PMID 19369080

Citations 8

Authors

Manolya D Ezgimen

Niklaus H Mueller

Tadahisa Teramoto

R Padmanabhan

Affiliations

Soon will be listed here.

Abstract

Detergents such as Triton X-100 are often used in drug discovery research to weed out small molecule promiscuous and non-specific inhibitors which act by aggregation in solution and undesirable precipitation in aqueous assay buffers. We evaluated the effects of commonly used detergents, Triton X-100, Tween-20, Nonidet-40 (NP-40), Brij-35, and CHAPS, on the enzymatic activity of West Nile virus (WNV) protease. Unexpectedly, Triton X-100, Tween-20, and NP-40 showed an enhancement of in vitro WNV protease activity from 2 to 2.5-fold depending on the detergent and its concentration. On the other hand, Brij-35, at 0.001% enhanced the protease activity by 1.5-fold and CHAPS had the least enhancing effect. The kinetic analysis showed that the increase in protease activity by Triton X-100 was dose-dependent. Furthermore, at Triton X-100 and Tween-20 concentrations higher than 0.001%, the inhibition of compound B, one of the lead compounds against WNV protease identified in a high throughput screen (IC(50) value of 5.7+/-2.5 microM), was reversed. However, in the presence of CHAPS, compound B still showed good inhibition of WNV protease. Our results, taken together, indicate that nonionic detergents, Triton X-100, Tween, and NP-40 are unsuitable for the purpose of discrimination of true versus promiscuous inhibitors of WNV protease in high throughput assays.

Citing Articles

Assessment of optimized FRET substrates as universal corona- and picornavirus main protease substrates for screening assays.

Fischer C, Van Oers T, van Belkum M, Lamer T, Romney A, Chen P RSC Adv. 2024; 14(48):35438-35446.

PMID: 39502179 PMC: 11537199. DOI: 10.1039/d4ra06573e.

High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.

Balasubramanian A, Manzano M, Teramoto T, Pilankatta R, Padmanabhan R Antiviral Res. 2016; 134:6-16.

PMID: 27539384 PMC: 5065773. DOI: 10.1016/j.antiviral.2016.08.014.

Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target.

Gurcha S, Usha V, Cox J, Futterer K, Abrahams K, Bhatt A PLoS One. 2014; 9(11):e113568.

PMID: 25409504 PMC: 4237437. DOI: 10.1371/journal.pone.0113568.

Human α-L-iduronidase uses its own N-glycan as a substrate-binding and catalytic module.

Maita N, Tsukimura T, Taniguchi T, Saito S, Ohno K, Taniguchi H Proc Natl Acad Sci U S A. 2013; 110(36):14628-33.

PMID: 23959878 PMC: 3767532. DOI: 10.1073/pnas.1306939110.

NMR analysis of a novel enzymatically active unlinked dengue NS2B-NS3 protease complex.

Kim Y, Gayen S, Kang C, Joy J, Huang Q, Chen A J Biol Chem. 2013; 288(18):12891-900.

PMID: 23511634 PMC: 3642332. DOI: 10.1074/jbc.M112.442723.

References

Chambers T, Grakoui A, Rice C . Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol. 1991; 65(11):6042-50. PMC: 250270. DOI: 10.1128/JVI.65.11.6042-6050.1991. View

Lindenbach B, Rice C . Molecular biology of flaviviruses. Adv Virus Res. 2003; 59:23-61. DOI: 10.1016/s0065-3527(03)59002-9. View

Taylor P, Culp J, Debouck C, Johnson R, Patil A, Woolf D . Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. J Biol Chem. 1994; 269(9):6325-31. View

Feng B, Shoichet B . A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc. 2006; 1(2):550-3. PMC: 1544377. DOI: 10.1038/nprot.2006.77. View

Johnston P, Phillips J, Shun T, Shinde S, Lazo J, Huryn D . HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol. 2008; 5(6):737-50. DOI: 10.1089/adt.2007.101. View

Debyser Z, Vandamme A, Pauwels R, Baba M, Desmyter J, De Clercq E . Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and.... J Biol Chem. 1992; 267(17):11769-76. View

Falgout B, Miller R, Lai C . Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J Virol. 1993; 67(4):2034-42. PMC: 240272. DOI: 10.1128/JVI.67.4.2034-2042.1993. View

Zhang L, Mohan P, Padmanabhan R . Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5. J Virol. 1992; 66(12):7549-54. PMC: 240467. DOI: 10.1128/JVI.66.12.7549-7554.1992. View

Manandhar S, Hildebrandt E, Schmidt W . Small-molecule inhibitors of the Rce1p CaaX protease. J Biomol Screen. 2007; 12(7):983-93. PMC: 2173876. DOI: 10.1177/1087057107307226. View

10.

McGovern S, Helfand B, Feng B, Shoichet B . A specific mechanism of nonspecific inhibition. J Med Chem. 2003; 46(20):4265-72. DOI: 10.1021/jm030266r. View

11.

Chambers T, Nestorowicz A, Amberg S, Rice C . Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol. 1993; 67(11):6797-807. PMC: 238121. DOI: 10.1128/JVI.67.11.6797-6807.1993. View

12.

Mueller N, Yon C, Ganesh V, Padmanabhan R . Characterization of the West Nile virus protease substrate specificity and inhibitors. Int J Biochem Cell Biol. 2006; 39(3):606-14. DOI: 10.1016/j.biocel.2006.10.025. View

13.

Leung D, Schroder K, White H, Fang N, Stoermer M, Abbenante G . Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem. 2001; 276(49):45762-71. DOI: 10.1074/jbc.M107360200. View

14.

Bartelma G, Padmanabhan R . Expression, purification, and characterization of the RNA 5'-triphosphatase activity of dengue virus type 2 nonstructural protein 3. Virology. 2002; 299(1):122-32. DOI: 10.1006/viro.2002.1504. View

15.

Bazan J, Fletterick R . Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology. 1989; 171(2):637-9. DOI: 10.1016/0042-6822(89)90639-9. View

16.

Borowski P, Niebuhr A, Mueller O, Bretner M, Felczak K, Kulikowski T . Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme. J Virol. 2001; 75(7):3220-9. PMC: 114115. DOI: 10.1128/JVI.75.7.3220-3229.2001. View

17.

Debyser Z, Pauwels R, Andries K, Desmyter J, Engelborghs Y, Janssen P . Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds. Mol Pharmacol. 1992; 41(1):203-8. View

18.

Roehrig J, Layton M, Smith P, Campbell G, Nasci R, Lanciotti R . The emergence of West Nile virus in North America: ecology, epidemiology, and surveillance. Curr Top Microbiol Immunol. 2002; 267:223-40. DOI: 10.1007/978-3-642-59403-8_11. View

19.

Goode D, Totten R, Heeres J, Hergenrother P . Identification of promiscuous small molecule activators in high-throughput enzyme activation screens. J Med Chem. 2008; 51(8):2346-9. DOI: 10.1021/jm701583b. View

20.

Mueller N, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson T, Padmanabhan R . Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother. 2008; 52(9):3385-93. PMC: 2533463. DOI: 10.1128/AAC.01508-07. View